Data Management And Sharing System of China National Clinical Research Center for Neurological Diseases
Surgical Management and Outcomes of Intracranial Chondromas: a Single-Center Case Series of 66 Patients
First author：Weng, Jian-Cong
Corresponding author：Zhang, Jun-Ting
essential_information
- Person in charge：Weng, Jian-Cong
- Data Sources： OTHERS
- Number of papers：OTHERS20190578
- Published time：2017-12-01
2017-12-01
Published articles
Journal：World Neurosurgery
Publication type: Research Article
IF(IF): 2.104
PMID: 28867324 Link To Pubmed Full text Download
Background And Purpose
Method
A retrospective review was performed in 66 patients who received surgical operations at our institute. Clinical charts and radiographs were reviewed, follow-up was performed, and adverse factors for progression-free survival (PFS) and overall survival were evaluated.
Conclusion
The therapeutic strategy for ICDs should be individualized and should consider preoperative variables. Gross total resection was attempted if the tumors were resectable; otherwise, subtotal resection was an alternative. In patients with partial resection and evident atypia/mitotic activity, consultation with an oncologist for radiotherapy was recommended.
Main results
The preoperative and postoperative Karnofsky performance status was 81.8 and 72.3, respectively. The mean tumor size was 3.5 cm. Gross total resection was achieved in 15 patients (22.7%). Six patients (10.3%) received postoperative radiation. After a mean follow-up duration of 85.5 months, recurrence occurred to 15 patients (28.8%) with surgery alone, and no recurrence was observed in patients receiving postoperative radiotherapy. Six patients (10.3%) died due to tumor progression. The risk factors affecting the PFS included age <33 years (hazard rate [HR] 6.876; 95% confidence interval [CI] 1.599-29.560; P = 0.010), tumor size ≥3.1 cm (HR 6.138; 95% CI 1.259-29.926; P = 0.025), tumor with evident atypia/mitotic activity (HR 4.672; 95% CI 1.352-16.152; P = 0.015), and partial resection (HR 12.841; 95% CI 3.004-54.896; P = 0.001). In all patients, the PFS rate was 75% at 5 years and 64% at 10 years; in addition, the overall survival rate was 93% at 5 years and 83% at 10 years.